Leukogene Therapeutics, Inc., an early‑stage oncology company developing MHC class II-engager immunotherapies for immunologically cold cancers, today announced two poster presentations at the American ...
MHC class II molecules are central to the adaptive immune response, serving as the means by which antigen-presenting cells, notably dendritic cells, display processed peptides to CD4+ T cells. This ...
Which came first, MHC class I or MHC class II? For decades, it has been debated which of these two similar classes came first in evolution. Now, Keiichiro Hashimoto and his group at Fujita Health ...
A new study sheds light on why some patients with the most aggressive form of ovarian cancer respond better to treatment than others. Tumors positive for a molecule called MHC class II are linked to ...
The study, according to the researchers, is the first to demonstrate the potential use of major histocompatibility complex class II (MHC-II) expression as a predictor of immunotherapy response in ...
(WNDU) - Genetic disorders are caused by an abnormality in a person’s DNA. 10 out of 1,000 babies born will be diagnosed with one. In fact, 17% of couples are at a high risk of transmitting a genetic ...
A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. This is an ASCO Meeting Abstract from the 2018 ASCO ...
MHC class II transactivator CIITA induces cell resistance to Ebola Virus and SARS-like coronaviruses
August 27, 2020 (Seattle, Wash.)--Discoveries from the Benaroya Research Institute at Virginia Mason (BRI) have identified a new cellular protection pathway that targets a common vulnerability in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results